Volver

Teva Pharma Industries Ltd ADR

Ticker: TEVA ISIN: US8816242098
Añadir al portafolio Análisis de cartera en 2min
Stock Large-cap Trading above 200-day average Near 52-week high
Capitalización
20,72 MM $
Forward P/E
6,96
Profit margin
-0,94%
Revenue growth QoQ
0,30%
Beta
0,62
37,34 $ 1,44%
Precio a fecha de 2026-08-21 · NYSE

Rendimiento por período

Rendimientos acumulados
1 Month +21,19%
6 Months +10,12%
1 Year +106,07%
5 Years +31,60% p.a.+294,30%
10 Years -2,70% p.a.-23,92%
Since inception +4,17% p.a.+177,74%
Rendimientos por año
YTD +19,64%
2025 +41,61%
2024 +111,11%
2023 +14,47%
2022 +13,86%
2021 -16,99%

Key stats

Market cap
20,72 MM
Beta
0,62
52-week range
12.47 - 22.80
50-day MA
16,72
200-day MA
17,21
Section 1

Business overview

Company profile data from fundamentals.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO to treat neurodegenerative and movement disorders " chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Country Israel
Exchange NYSE
Section 2

Financial quality

Profitability and balance-sheet quality indicators from reported fundamentals.

Profitability

ROE -2,42%
ROA 5,37%
Profit margin -0,94%
Operating margin 21,41%
PEG ratio 1,29
Revenue/share TTM 14,61
Revenue TTM 16,63 MM
EBITDA 4,52 MM
Gross profit TTM 8,25 MM
Beta 0,62

Valuation

Trailing P/E 0,00
Forward P/E 6,96
P/B 3,03
P/S 1,25
EV/EBITDA 19,12
EV/Revenue 2,18

ESG Scores

Total ESG 58,8
Environment 77,0
Social 47,2
Governance 65,3
Section 3

Earnings

Earnings metrics from company highlights and earnings datasets.

EPS estimate (current year) 2,58
Quarterly earnings growth 40,00%
Revenue TTM 16,63 MM
Reported quarters 120
Section 4

Dividends & corporate actions

Dividend and split fields from fundamentals.

Forward annual div. yield 0,00%
Ex-dividend date 2017-11-27
Split factor 2:1
Last split date 2004-07-01
Section 5

Ownership / analyst view

Institutional ownership and analyst estimate fields when available.

Analyst

Analyst target price 23,56 $
Analyst rating 4.4546

Ownership & short interest

Shares outstanding 1,15 MM
Shares float 1,14 MM
Institutional ownership 66,22%
Insider ownership 0,20%
Short ratio 4,27
Short % of float 4,37%

Details

Instrument metadata and source update timestamps.

Symbol TEVA
Name Teva Pharma Industries Ltd ADR
Asset type STOCK
Exchange NYSE
Currency USD
ISIN US8816242098
Country USA
Code + exchange TEVA.NYSE
Fundamentals updated 2025-08-19

La información proporcionada en esta plataforma es solo para fines informativos y no debe considerarse como asesoramiento financiero o de inversión. Insightfolio no ofrece asesoramiento financiero, recomendaciones personalizadas ni orientación sobre la compra, tenencia o venta de activos financieros. Las herramientas y contenidos son únicamente educativos y no están adaptados a las circunstancias, necesidades financieras u objetivos personales.

Insightfolio no asume ninguna responsabilidad por la precisión, integridad o fiabilidad de la información presentada. Es responsabilidad exclusiva de los usuarios verificar la información y tomar decisiones independientes basándose en su propia investigación y consideración. El uso de esta plataforma no reemplaza la consulta con profesionales financieros cualificados.

Invertir implica riesgos. Los usuarios deben ser conscientes de que el valor de las inversiones puede fluctuar y que los rendimientos pasados no son garantía de resultados futuros. Las decisiones de inversión deben basarse en objetivos financieros personales, tolerancia al riesgo y una evaluación independiente de la información relevante.

Insightfolio no respalda ni garantiza la idoneidad de ningún producto financiero, valor o estrategia en particular. Cualquier proyección, pronóstico o escenario hipotético presentado en la plataforma es solo ilustrativo y no constituye una garantía.

Al acceder a los servicios, información o contenido ofrecido por Insightfolio, los usuarios reconocen y aceptan los términos de este aviso legal. Si no estás de acuerdo con estos términos, por favor no uses nuestra plataforma.

Logotipos de instrumentos proporcionados por Elbstream.